Please login to the form below

Not currently logged in
Email:
Password:

Pfizer phase III Lyrica success

Pfizer has recorded positive results in a phase III trial of fibromyalgia treatment Lyrica

Pfizer has recorded positive results in a phase III trial of Lyrica (pregabalin), a potential new treatment for fibromyalgia -  a disabling disorder that adversely affects quality of life.

The study demonstrated a statistically significant reduction in the endpoint mean pain score recorded by participants, with the drug demonstrating efficacy and safety.

The drug was compared to placebo, with 501 subjects involved across 45 investigative sites in Japan.

"We are pleased with the top-line results of this study and look forward to more fully understanding the potential benefits that Lyrica may bring to fibromyalgia patients in Japan," said Dr Akihisa Harada, vice president, head of development, at Pfizer Japan.

The most common adverse events in the study were somnolence, dizziness, weight increased, constipation, feeling abnormal, edema peripheral and blurred vision.

7th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics